Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.affinitybiologicals.com
Number of Employees: 25
Year Founded: 1987
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Affinity Biologicals Inc. manufactures research and diagnostic products in the fields of hemostasis, thrombosis, and coagulation. The company specializes in polyclonal antibodies, EIAs, deficient plasmas, enzyme linked immuno-sorbent assay (ELISA) kits, reagents, and control plasmas. It offers coagulation related antibodies, matched-pair antibody sets for ELISA, depleted/deficient plasmas, protease inhibitor deficient plasmas, ELISA kits, coagulation controls and calibration plasmas, and proficiency testing materials. The company also provides medical device manufacturing services; and polyclonal antibody production, contract manufacturing, specialty plasma and control, and protein purification services. It sells its products through a network of branded and private-label distributors in North America and internationally. Affinity Biologicals Inc. was founded in 1987 and is headquartered in Ancaster, Canada. As of November 1, 2018, Affinity Biologicals Inc. operates as a subsidiary of Precision BioLogic Inc.


Financial Information (Currency: CAD, in mm)
Total Revenue
 9.5
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 25
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
No Key Professionals have been profiled.


Primary Industry Classification
Health Care Supplies


Primary Office Location
1395 Sandhill Drive | Ancaster, ON | L9G 4V5 | Canada
Phone: 905-304-9896   Fax: 905-304-9897

Parent Company
Precision BioLogic Inc.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-01-2018
Nov-01-2018
Merger/Acquisition
Target
Affinity Biologicals Inc.
Precision BioLogic Inc.

-
Jan-9-2002
Cancelled
Merger/Acquisition
Target
Affinity Biologicals Inc.
Corgenix Medical Corp.

2.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-05-2020
Company Conference Presentations
Affinity Biologicals Inc. Presents at MD Life Sciences Bio Innovation virtual conference, Oct-05-2020 03:00 PM
Nov-01-2018
M&A Transaction Closings
Precision BioLogic Inc. acquired Affinity Biologicals Inc.
May-29-2014
Product-Related Announcements
Affinity Biologicals Introduces an Upgraded Collection of ELISA Kits
Jun-13-2002
M&A Transaction Cancellations
Cancelled Merger/Acquisition Transaction - Target: Affinity Biologicals, Inc.; Buyer(s): Corgenix Medical Corp.; Transaction Size: $2 mm
Jan-09-2002
M&A Transaction Announcements
Announced Merger/Acquisition Transaction - Target: Affinity Biologicals, Inc.; Buyer(s): Corgenix Medical Corp.; Transaction Size: $2 mm


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 18, 2023 02:36 AM
Affinity Biologicals Inc.
Affinity Biologicals Inc
Reports
34
GlobalData

Dec 14, 2022 06:30 PM
Affinity Biologicals Inc.
Affinity Biologicals Inc
Reports
34
GlobalData

Sep 19, 2022 06:59 AM
Affinity Biologicals Inc.
Affinity Biologicals Inc
Reports
34
GlobalData

Jun 13, 2022 03:12 AM
Affinity Biologicals Inc.
Affinity Biologicals Inc
Reports
34
GlobalData

Mar 25, 2022 01:37 AM
Affinity Biologicals Inc.
Affinity Biologicals Inc
Reports
34
GlobalData

Dec 15, 2021 05:07 AM
Affinity Biologicals Inc.
Affinity Biologicals Inc
Reports
26
GlobalData

Sep 13, 2021 09:27 AM
Affinity Biologicals Inc.
Affinity Biologicals Inc
Reports
15
GlobalData

Jun 16, 2021 08:11 AM
Affinity Biologicals Inc.
Affinity Biologicals Inc
Reports
16
GlobalData

Dec 09, 2020 02:56 AM
Affinity Biologicals Inc.
Affinity Biologicals Inc
Reports
18
GlobalData

Sep 11, 2020 02:58 AM
Affinity Biologicals Inc.
Affinity Biologicals Inc
Reports
18


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
No Key Executives and Professionals exist.

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
